



DECIPHER PROSTATE BIOPSY

AFTER [POSITIVE] BIOPSY
TREATMENT INFORMATION



The Decipher Biopsy tests help you and your doctor decide next steps in your prostate cancer care.



KNOW YOUR PROSTATE CANCER RISK

The Decipher Biopsy test is the most accurate way to determine the aggressiveness of your prostate cancer and assess your personal risk of metastasis. Using advanced whole genome technology, Decipher Biopsy provides valuable information to you and your doctor so that you can make more informed decisions about your next steps in managing your prostate cancer.



- Is active surveillance through PSA monitoring sufficient for me?
- Is localized treatment sufficient?
- Do I need more than one therapy (multi-modal therapy)?

Decipher Classification	Patient Management Recommendations
Decipher Biopsy Low Risk	Favorable prognosis – may be suitable for active surveillance and may have excellent outcomes with local therapy alone ¹⁻³
Decipher Biopsy High Risk	Unfavorable prognosis – may not be suitable for active surveillance and may benefit from intensification with multi-modal therapy ¹⁻³

ANSWER THE FOLLOWING QUESTIONS TO DETERMINE IF DECIPHER® BIOPSY IS RIGHT FOR YOU:

Y N

Have you had a prostate biopsy positive for cancer?

Did your doctor indicate that any of the following apply to you after biopsy?

▪ **Very Low Risk**

Prostate Cancer Stage T1c tumor,
AND biopsy Gleason score of 6 or less,
AND PSA level less than 10ng/mL,
AND presence of disease in fewer than 3 biopsy cores,
AND less than 50% prostate cancer involvement in any core,
AND PSA density less than 0.15 ng/mL/g.

▪ **Low Risk**

Prostate Cancer Stage T1a, T1b, T1c, or T2a tumor,
AND PSA level less than 10ng/mL,
AND biopsy Gleason score of 6 or less

▪ **Favorable Intermediate Risk**

T2b-T2c,
OR Gleason score 3+4=7/ grade group 2,
OR PSA 10-20ng/mL,
AND percentage of positive biopsy cores <50%

If you answered **yes** to any of the questions, then the Decipher Biopsy test may play a role in determining what type of therapy you may need.

References

1. Klein, E.A., et al., Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. Urology, 2016; DOI: <http://dx.doi.org/10.1016/j.urol.2016.01.012>
2. Knudsen, B.S., et al., Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. Journal of Molecular Diagnostics, 2016; In Press.
3. Lee, Hak J., et al., "Evaluation of a Genomic Classifier in Primary Tumor and Lymph Node Metastases in Pre- and Post-Radical Prostatectomy Tissue Specimens from Patients with Lymph Node Positive Prostate Cancer" presented at the 2015 annual meeting of the American Society of Clinical Oncology.



Contact your doctor to find out how Decipher might play a role in your treatment planning or contact the GenomeDx Customer Support Team at 1.888.792.1601 (toll-free) or e-mail customersupport@genomedx.com.

WHAT IS THE DECIPHER TEST?

Based on the patient's personal tumor-based genomics, Decipher Prostate Cancer Classifier:



DECIPHER BIOPSY

- Performed on your prostate biopsies diagnosed as positive for cancer
- May help determine which men may be suitable candidates for active surveillance, which may need local therapy, and which men may need intensified therapy



ACCESS FOR ALL PATIENTS

- Private Insurance Coverage
- Proven and comprehensive financial assistance for patients



To learn more about Decipher, contact the GenomeDx Customer Support Team at 1.888.792.1601 (toll free) or email at customersupport@genomedx.com.



Copyright © 2018 GenomeDx Biosciences Corp.
DPTBO2018 0307